Quarterly report pursuant to Section 13 or 15(d)

Segment Information

v3.19.1
Segment Information
6 Months Ended
Feb. 28, 2019
Notes to Financial Statements  
Segment Information

The Company’s operations involve the development and usage, including licensing, of its proprietary nutrient infusion Technology. Lexaria is centrally managed and its chief operating decision makers, being the president and the CEO, use the consolidated and other financial information supplemented by revenue information by category of alternative health consumer products and technology licensing to make operational decisions and to assess the performance of the Company. The Company has identified two reportable operating segments: Intellectual Property Licensing and Consumer Products. Licensing revenues are significantly concentrated on five licensees.

 

    IP Licensing     Consumer Products     Corporate     Consolidated Total  
External Revenue     32,000       5,558       -       37,558  
CoGS     -       (4,848 )     -       (4,848 )
Operating Expenses     (719,358 )     (61,455 )     (1,106,399 )     (1,887,212 )
Segment Loss     (687,358 )     (60,745 )     (1,106,399 )     (1,854,502 )
Total Assets     338,298       108,018       3,827,227       4,273,543